NP / PA
Johnson, Karen
Johnson, Karen was paid $208K by Medicaid between Mar 2019 and Dec 2024, across 22 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 68% of everything it billed.
33Billing provider infoJOHNSON, KAREN
PALOS HEIGHTS, IL 60463
PALOS HEIGHTS, IL 60463
33aNPI1831670942assigned 08/27/2018
33bProvider typeFamily Nurse Practitioner
28Total paid$208K
24GClaims10,838
24DCodes billed22
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in Illinois
Rank by total paid#342 of 3,353
Median peer was paid$25K
This provider vs. median8.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 411 | $13K | |
| 2020 | 1,911 | $25K | |
| 2021 | 2,742 | $56K | |
| 2022 | 2,820 | $56K | |
| 2023 | 1,647 | $30K | |
| 2024incomplete | 1,307 | $29K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 68% | 2,854 | 2,285 | $141K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6.8% | 276 | 173 | $14K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.0% | 284 | 223 | $13K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.2% | 142 | 117 | $11K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.8% | 101 | 79 | $8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.6% | 314 | 261 | $8K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.4% | 84 | 59 | $7K |
| 87999 | <1% | 125 | 109 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 66 | 47 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 21 | 15 | $2K |
| 96127 | <1% | 65 | 45 | $949.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 56 | 50 | $788.14 |
10 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.